OST-122 is under clinical development by Oncostellae and currently in Phase II for Ulcerative Colitis. According to GlobalData, Phase II drugs for Ulcerative Colitis have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how OST-122’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OST-122 overview
OST-122 is under development for the treatment of inflammatory bowel disease, fibrosis, colorectal cancer and ulcerative colitis. It is administered through oral route. The drug candidate acts by targeting AMPK related protein kinase 5 (ARK5), janus kinase 3 (JAK3) and tyrosine kinase 2 (TYK2).
Oncostellae overview
Oncostellae, is a biotechnology company that focused on development of small molecule drugs for the treatment of cancer. The company is headquartered in Spain.
For a complete picture of OST-122’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.